Reduction of CD8+ T lymphocytes in multiple sclerosis patients treated with dimethyl fumarate

Neurology: Neuroimmunology and NeuroInflammation

Volumn 2, Issue 3, 2015, Pages e76-

  Spencer, Collin M ^a   Crabtree Hartman, Elizabeth C ^a   Lehmann Horn, Klaus ^a   Cree, Bruce A C ^a   Zamvil, Scott S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; CD56 ANTIGEN; FUMARIC ACID DIMETHYL ESTER;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; BASOPHIL; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; EOSINOPHIL; FEMALE; HUMAN; LEUKOCYTE; LYMPHOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; MALE; MONOCYTE; MULTIPLE SCLEROSIS; NATURAL KILLER CELL; NEUTROPHIL; PRIORITY JOURNAL; TREATMENT DURATION;

EID: 84937389250     PISSN: None     EISSN: 23327812     Source Type: Journal    
DOI: 10.1212/NXI.0000000000000076     Document Type: Article

References (17)

1. Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012;367:1087-1097.
2. Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012;367:1098-1107.
3. van Oosten BW, Killestein J, Barkhof F, Polman CH, Wattjes MP. PML in a patient treated with dimethyl fumarate from a compounding pharmacy. N Engl J Med 2013;368:1658-1659.
4. Ermis U, Weis J, Schulz JB. PML in a patient treated with fumaric acid. N Engl J Med 2013;368:1657-1658.
5. Sweetser MT, Dawson KT, Bozic C. Manufacturer's response to case reports of PML. N Engl J Med 2013;368:1659-1660.
6. U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA warns about case of rare brain infection PML with MS drug Tecfidera (dimethyl fuma-rate). Available at: http://www.fda.gov/Drugs/DrugSafety/ucm424625.htm. Accessed November 25, 2014.
7. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Safety Review, BG00012, NDA 204063. 2013.
8. Lehmann JC, Listopad JJ, Rentzsch CU, et al. Dimethylfu-marate induces immunosuppression via glutathione depletion and subsequent induction of heme oxygenase 1. J Invest Dermatol 2007;127:835-845.
9. Linker RA, Lee DH, Ryan S, et al. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain 2011;134:678-692.
10. Bruck W, Gold R, Lund BT, et al. Therapeutic decisions in multiple sclerosis: moving beyond efficacy. JAMA Neu-rol 2013;70:1315-1324.
11. Ma Q, Battelli L, Hubbs AF. Multiorgan autoimmune inflammation, enhanced lymphoproliferation, and impaired homeostasis of reactive oxygen species in mice lacking the antioxidant-activated transcription factor Nrf2. Am J Pathol 2006;168:1960-1974.
12. Tsai JJ, Dudakov JA, Takahashi K, et al. Nrf2 regulates haematopoietic stem cell function. Nat Cell Biol 2013;15: 309-316.
13. Longbrake EE, Cross AH. Dimethyl fumarate associated lymphopenia in clinical practice. Mult Scler Epub 2014 Nov 28. pii: 1352458514559299.
14. Hoxtermann S, Nuchel C, Altmeyer P. Fumaric acid esters suppress peripheral CD4-and CD8-positive lymphocytes in psoriasis. Dermatology 1998;196:223-230.
15. Major EO. Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu Rev Med 2010;61:35-47.
16. Du Pasquier RA, Kuroda MJ, Zheng Y, Jean-Jacques J, Letvin NL, Koralnik IJ. A prospective study demon strates an association between JC virus-specific cytotoxic T lymphocytes and the early control of progressive multifocal leukoencephalopathy. Brain 2004;127: 1970-1978.
17. Tecfidera [package insert]. Cambridge, MA: Biogen Idec; 2014.